METASTATIC CANCER

This early-stage study tested a new drug called HMBD-002, alone or with another drug (pembrolizumab), in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, …

This study tested a new, very precise type of radiation called SABR in 13 adults with cancer that had spread to more than 10 spots in the body. The main goal was to find the safest dose and see if it could be given without causing severe side effects. Researchers also measured qu…

This early-phase study tested a new treatment called VE800, made from live bacteria, combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goals were to check safety and see if tumor…

This study tested whether a single, high-dose radiation treatment can destroy limited cancer spread (1-5 tumors) in 150 adults with metastatic cancer. The goal was to control or eliminate visible tumors and extend survival without needing lifelong medication. Results were measure…

This early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 adults with advanced or metastatic solid tumors, including lung cancer. The goal was to find safe doses for future larger studies. The tr…

This early-phase trial tested whether adding thiopurine drugs (6-MP and 6-TG) to the immunotherapy atezolizumab could help shrink advanced solid tumors that have a moderate number of genetic mutations. The study enrolled 18 adults with metastatic cancers that had no standard cure…

This early-phase trial tested an experimental pill called ART4215 in 93 people with advanced or metastatic solid tumors (including breast cancer). The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs. The study is now comp…

This early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…

This study tested whether adding a third drug, ipilimumab, to a two-drug combination (atezolizumab and bevacizumab) helps people with advanced liver cancer live longer. 229 patients received either the two-drug or three-drug regimen. The goal was to see if the triple therapy impr…

This early-phase study tested a new immune cell treatment called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The approach uses…

This study looked at whether adding targeted radiation (SBRT) to standard immunotherapy can improve tumor shrinkage in people with advanced cancer that has spread. About 106 participants received either immunotherapy alone or combined with radiation. The goal was to see if the co…

This study tested a new drug called ozuriftamab vedotin in 42 people with head and neck cancer that had come back or spread. The goal was to see if the drug could shrink tumors and how safe it was. Researchers measured how many patients responded to treatment and tracked side eff…

This study tested the drug sunitinib in 21 people with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors. Sunitinib works by blocking blood flow to cancer cells and stopping them from growing. The study was completed and looked …

This early-stage study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking for signs that the drug might shr…

This early-phase study tested a new treatment called NG-350A, a virus designed to activate immune cells inside tumors, combined with the immunotherapy drug pembrolizumab. It involved 14 people with advanced epithelial cancers that had stopped responding to standard treatments. Th…

This early-phase study tested a new drug called MRX-2843 in 42 adults with advanced or metastatic solid tumors that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. Researchers monitored side effects and how the drug move…

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with metastatic colorectal cancer that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The study is complete and h…

This study looked at how safe and effective two targeted drugs, trastuzumab deruxtecan and sacituzumab govitecan, are for people with advanced breast cancer. Researchers reviewed medical records of 312 patients who had already tried other treatments. The goal was to see side effe…

This study tested whether giving a booklet-question list to people with advanced cancer or their families helps them ask more questions during a palliative care visit. About 121 participants were involved. The goal was to see if the booklet improves communication about prognosis …

This study tested a program called ED GOAL that helps older adults with serious illnesses like heart failure or cancer talk about their care wishes while in the emergency department. Researchers worked with 141 patients to see if the program increased how often they discussed the…

This study looked at 159 people with advanced colorectal, pancreatic, biliary, or esophageal cancers to see if simple blood tests (tumor markers and liquid biopsies) and patient-reported symptoms could predict whether the cancer would get worse. Researchers compared changes in th…

This study tested whether a special 'return home' consultation, involving the patient, their regular doctor, and a cancer specialist, could reduce unplanned hospital visits for people with metastatic cancer. 667 hospitalized patients were randomly assigned to either this organize…